INNOVATIVE APPROACH TO DIAGNOSIS, RISK FACTOR, AND MANAGEMENT OF GESTATIONAL DIABETES MELLITUS (GDM)—MOTHER AND OFFSPRING

Krishna Babu Ojha[1*], Hritik Verma[2], Ravi Rajput[3], Soni Jadoun[4]

1-Reseach Scholar. Rajiv Academy for Pharmacy , Delhi road, P.O. Chhatikara Mathura-281001 (U.P), India Email- krishnababuojha08@gmail.com
2-Reseach Scholar. Rajiv Academy for Pharmacy , Delhi road, P.O. Chhatikara Mathura-281001 (U.P), India Email- vermahrithik.hv@gmail.com
2- Head of Department. Amardeep College Of Pharmacy, Jalesar Road, Firozabad-283203 (U.P), India Email- ravirjpt@gmail.com
3- Research Scholar. Amardeep College Of Pharmacy, Jalesar Road, Firozabad-283203 (U.P), India Email- sonijadoun123654@gmail.com

ABSTRACT

BACKGROUND: One of the main barriers for obtaining improved maternal and child health is Gestational Diabetes Mellitus. it affects around 5% of pregnancies that increases the risk of caesarean and surgical vaginal birth, macrosomia, shoulder dystocia, neonatal hypoglycaemia, and hyperbilirubinemia for both the mother and the unborn child. In this review article we focused on the various parameter that affects Gestational diabetes mellitus like, pathophysiology, epidemiology, risk factors and treatment.
BODY: An extensive literature review was done from the standard databases such as Scopus, Elsevier, and PubMed using standard keywords “Gestational Diabetes”, “Diabetes”, “Pregnancy disorder”. Here, we explore the effects of Gestational Diabetes Mellitus on long-term maternal and newborn outcomes as well as health concerns that will probably last into the next generation. We discuss current clinical survey data and model of Gestational Diabetes Mellitus to better understand the underlying pathophysiology of the disease and the timely need to expand our scientific toolbox in order to identify strategies to prevent and treat Gestational Diabetes Mellitus.
CONCLUSION: While discussing about the gestational diabetes mellitus with the advance clinical care, in addition to the challenges currently faced in the Epidemiology, and techniques of diagnosis, Pathophysiology, risk factor, management of Gestational Diabetes Mellitus.

KEYWORDS: Gestational diabetes, pregnancy, epidemiology, pathophysiology, diagnosis, prevention, management.



1. BACKGROUND:

Approximately 5% of pregnancies result in gestational diabetes mellitus (GDM), though statistics can vary greatly depending on the criteria utilised and the demographics of the population. As long as the obesity pandemic persists, the prevalence is anticipated to rise. GDM-affected pregnancies increase the risk of caesarean and surgical vaginal birth, macrosomia, shoulder dystocia, neonatal hypoglycaemia, and hyperbilirubinemia for both the mother and the unborn child. Both obesity among women of childbearing age and hyperglycaemia in pregnancy (HIP) are rising to epidemic levels globally (1, 2). We are adhering to the diagnostic guidelines for HIP provided by the International Federation of Gynaecology and Obstetrics (FIGO) (3) for our current study, which includes any level of glucose increase in pregnancy as a component of the general description of HIP. According to the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study (4, 5), maternal BMI and hyperglycaemia had similar relationships with pregnancy problems. Both had a higher incidence of excessive foetal growth, primary caesarean delivery, clinical neonatal hypoglycaemia and foetal obesity, neonatal hyperinsulinemia, and hypertensive disorders of pregnancy. The relationship between high blood sugar and unfavourable outcomes is often linear, however the relationship between BMI and outcomes has a quadratic pattern with decreasing increments at the highest BMI categories (6). Additionally, it may be possible to identify a distinct group of pregnant women with glucose levels that are within the normal range in the early stages of pregnancy but who have a high risk of developing "standard GDM," which is typically diagnosed at around 24 to 28 weeks' gestation, using clinical characteristics and biochemical tests. Practically speaking, it makes sense to focus early intervention efforts on women with pre-pregnancy hyperglycaemia, early-stage GDM, and

high-risk GDM. ECVs contain a significant amount of micro RNAs, which are crucial for the metabolism of glucose. According to Yoffe et al exploratory case-control study, micro-RNA-223 and micro-RNA 23a in first-trimester blood samples were highly predictive of later GDM (AUROC 0.91); (7). This result for micro-RNA-233 has been corroborated by a recent cohort research (8). The overall connections between non-coding RNAs and GDM have lately been studied in depth, and these results are encouraging (9). These encouraging results from modest studies need to be verified in separate cohorts, as is the case with other biomarkers. In order for the essential assays to be used in normal diagnostic laboratories at low cost and high throughput, they will also need to be updated.

2. EPIDEMIOLOGY:

Finding the true prevalence of GDM is difficult. Depending on how diverse and moral the population, the frequency varies around the globe and even within a nation's population. Therefore, compared to Caucasian women, the prevalence is higher among African (American), Hispanic (American), Pacific Islander, Native American, and Asian women (South or East) in the United States (10). Additionally, different screening methods (universal or selective), diagnostic standards, and the incidence of T2DM in a given nation all affect GDM prevalence differently. While statistics from developed nations are rarely reported, those from western nations are frequently. Jiwani et al. (11) and Macaulay et al. (12) recently attempted to ascertain the prevalence of GDM globally, including developing nations. The prevalence was discovered to vary between 5% in nations like Pakistan, Belgium, Denmark, Estonia, Ireland, South Korea, South Africa, and the United Kingdom, 10% in nations like Italy, Turkey, Brazil, United States, Morocco, and Australia, and 20% in nations like Bermuda and Nepal. According to a recent data According to the International Diabetes Federation, pregnancy-related hyperglycemia complicated 16% of live deliveries globally in 2013 (13), and it is most likely that the prevalence of GDM will rise as a result of the rise in risk factors like obesity and inactivity. The interaction of these environmental and genetic risk factors raises the possibility of intricate molecular mechanisms underlying GDM. According to 20 cohort studies from North America, Australia and Europe, were combined for a meta-analysis, women who are overweight, obese, or severely obese had a two to eight times higher risk of developing type 2 diabetes (GDM) than women with a normal body mass index (BMI) (14).



Figure 1. Data of cohort studies, shows % of women with GDM

3. GDM DIAGNOSIS:

3.1 **Glycosylated haemoglobin (HbA1c)-** An obvious substitute for this test is glycosylated haemoglobin (HbA1c), which is frequently used to diagnose diabetes outside of pregnancy. It appears to be of minimal usefulness, with the exception of early pregnancy detection of undiagnosed hyperglycaemia, and performs poorly in both the prediction of OGTT diagnosed GDM and the prediction of pregnancy outcomes (15, 16).

3.2 **Oral Glucose Tolerance Test (OGTT)-** The World Health Organization (WHO) (17, 18), the International Association of Diabetes in Pregnancy Study Groups (IADPSG) (19), and FIGO (20) all support "one step" OGTT testing, using thresholds of 5.1 mmol/L fasting; 10.0 mmol/L at 1 h; and 8.5 mmol/L at 2 h after a 75 gramme glucose load for diagnosis of GDM. Clearly, a cheaper, more accurate, non-fasting test would be preferred as the glucose tolerance test is cumbersome, resource-intensive, and fairly poorly reproducible (21, 22). Self-administered home OGTTs tend to function as well as laboratory testing and offer additional convenience.

3.3 **Oral Glucose Challenge Test (OGCT)-** The diagnostic technique varies significantly between the USA (23) and Canada (24) which often choose two-step testing employing a non-fasting, one-hour "glucose challenge" test (GCT), followed by an OGTT (100 gram or 75 gram) if the GCT result exceeds specified thresholds. The need for early testing as well as testing during the conventional 24 to 28 week window has also been endorsed by the IADPSG, WHO, and FIGO.

4. PATHOPHYSIOLOGY-

Maternal tissues grow gradually less responsive to insulin during a typical pregnancy. This is thought to be brought on in part by hormones produced by the placenta and in part by other, as yet unidentified, mechanisms connected to pregnancy and obesity. The two primary sites for whole-body glucose disposal are skeletal muscle and adipose tissue. Normal pregnancy causes a 50% reduction in insulin-mediated whole-body glucose clearance, necessitating a 200%–250% increase in insulin secretion from the mother in order to maintain a euglycemic condition. [17] A progressive IR begins to form about the halfway point of a typical pregnancy and continues to worsen throughout the third trimester (25). Possible causes of IR in pregnancy include hormones and adipokines released from the placenta, such as tumour necrosis factor (TNF)-, human placental lactogen, and human placental growth hormone. The glucose insulin balance is also upset during pregnancy due to higher levels of oestrogen, progesterone, and cortisol (26). A woman's pancreas secretes more insulin during pregnancy to make up for the peripheral IR. When a woman's pancreas is unable to produce enough insulin to cope with the metabolic load of IR, GDM begins to develop. This condition of relative glucose intolerance is also accompanied by increased maternal adipose accumulation, decreased activity, and increased caloric consumption.



Figure 2. A precursor to the vicious cycle of transgenerational obesity and diabetes is gestational diabetes mellitus (GDM). The three crucial windows of opportunity to end the cycle are included in the general pathophysiology of GDM that is displayed. Polycystic ovarian syndrome (PCOS).

When a pregnant woman is unable to produce enough insulin to counteract this natural insulin resistance, gestational diabetes mellitus (GDM) develops. Both lean and obese women experience GDM. However, it is thought that these populations have different pathophysiology's for the condition. The pathogenesis of pregnancy-induced insulin resistance in obese women is essentially defined by the pre-existing elevated level of insulin resistance amplifying the pregnancy-induced insulin resistance. One known contributing cause to the metabolic syndrome is the elevated level of insulin resistance. The same components appear to be at play in slim women, although a failure in the first-phase insulin response is more significant (27). These flaws combine to undermine insulin's ability to maintain glucose levels, which causes maternal hyperglycaemia. The placenta transmits glucose to the developing foetus. As a result, maternal hyperglycaemia prompts foetal hyperinsulinemia to balance out the excessive placental glucose transport. Foetal macrosomia (birth weight over 4000 g) is caused by the elevated insulin level in the foetus (28).

5. RISK FACTORS FOR GDM.

There are several risk factors connected to the emergence of GDM. Obesity, advanced maternal age, prior GDM, significant family history of diabetes, belonging to an ethnic group with a higher incidence of T2DM, polycystic ovarian syndrome, and chronic glucosuria are the most frequent risk factors. Other risk factors for GDM include a history of having large babies (birth weight >4000 g), recurrent abortion, unexplainable stillbirths, high blood pressure in the past, or pregnancy-related high blood pressure (26).



Figure 3. several risk factors connected to the emergence of GDM.

Pregnancy-related hypertensive diseases like gestational hypertension, pre-eclampsia, and eclampsia are more common in women with GDM (29). A higher risk of polyhydramnios could result in a higher risk of preterm labour. In GDM, excessive foetal growth is still a significant perinatal issue. Birth trauma, maternal morbidity from caesarean births, shoulder dystocia, and neonatal hypoglycaemia are all effects of excessive foetal development (29). Neonatal morbidities such as hyperbilirubinemia, hypocalcaemia, erythema, and respiratory distress syndrome may also be more common in new-borns of GDM-affected mothers (29). Diabetes and cardiovascular disease in mothers are two long-term effects of GDM, while obesity and diabetes are long-term effects in children (30) Given that gestational diabetes typically develops in the latter half of the second trimester, when development is complete, congenital abnormalities do not progress more frequently in people with GDM.

6. MANAGEMENT OF GDM-

Glycaemic control is the core of GDM treatment. Lifestyle measures, such as regular exercise and medical nutrition therapy, are the first line of treatment for GDM. To ensure that the glycaemic goals are met, patients must periodically check their blood sugar levels at home. With these measures, medical treatment should be started if the glycaemic targets are not met. In comparison to standard care, the key composite result of child mortality, bone fracture, shoulder dystocia, and nerves palsy was linked with a 67% reduction with intervention that included food advising, blood glucose monitoring, and insulin administration as needed. Reduced rates of congenital malformations and average birthweight were also observed. The Maternal-Fetal Medicine Units Network randomised trial, which had 958 women with "mild" GDM, also showed similar advantages (i.e., normal fasting glucose levels on OGTT). In comparison to conventional care, a similar intervention package was linked to lower clinical outcomes, such as macrosomia, Caesarean birth, shoulder dystocia, and preeclampsia (31, 32). Figure 4.(32)

Figure 4. Selected Neonatal and Maternal Results from the Unite Network for Maternal-Fetal Medicine Trail[c]

	Treatment group	Control group	Relative risk	P Value	Refrences
Neonatal Outcomes [a]	*n=485*	*n=473*			ref .[32]
Composite perinatal end point[b]	149/460 (32.4)	163/440 (37.0)		0.87	
Birth Weight (g)	3302 ± 502.4	3408 ± 589.4		<0.001	
Birth Weight >4000 g	28/477 (5.9)	65/454 (14.3)	0.41 (0.26-0.66)	<0.001	
Large for gestational age	34/477 (7.1)	66/454 (14.5)	0.49 (0.32-0.76)	<0.001	
Fat mass (g)	427.0 ± 197.9	464.3 ± 222.3		0.003	
Maternal outcomes	*n=476*	*n=455*			
Caesarean delivery	128 (26.9)	154 (33.8)	0.79 (0.64-0.99)	0.02	
Shoulder dystocia	7 (1.5)	18 (4.0)	0.37 (0.14-0.97)	0.02	
Preeclampsia	12 (2.5)	25 (5.5)	0.46 (0.22-0.97)	0.02	
Preeclampsia or gestational hypertension	41 (8.6)	62 (13.6)	0.63 (0.42-0.96)	0.01	
Weight gain (kg)	2.8 ± 4.5	5.0 ± 3.3		<0.001	

[a]At least partial delivery information was missing for 10 women in the treatment group and 19 women in the control group.

[b]Still birth, infant death, hypoglycaemia, hyperbilirubinemia, an elevated cord c-peptide level, and birth trauma were all part of the composite perinatal outcome.

[c]Data are displayed as n/N (%), or n (%) or mean ± SD.

6.1 **Exercise**. Glycaemic control in GDM has been demonstrated to improve with exercise. If there are no medical or obstetrical contraindications, a woman with GDM is advised to engage in daily workout for at least 30 minutes. It is beneficial to GDM patients' achievement of their glycaemic goals to advise them to walk briskly or perform arm exercises while sitting in a chair for at least ten minutes following each meal (33,34).

6.2 **Dietary Intervention-** An crucial part of managing GDM is lifestyle intervention, which includes dietary change, physical exercise, and weight management. According to estimates, this approach may be sufficient to help 70 to 85% of women who were diagnosed based on ADA criteria reach their blood glucose goals (35). To improve mother and foetal outcomes, gestational weight gain goals should be established on an individual basis. Although it does not specifically address GDM, an Institute of Medicine recommendation suggests weight increase targets based on pre-pregnancy BMI (35).

A recent meta-analysis of randomised controlled trials found that dietary intervention was associated with better mean maternal fasting blood glucose (13 studies; 4.07 mg/dl, 95% CI7.58 to 0.57, P = 0.02) and post - prandial glucose (9 studies; 7.78 mg/dl, 95% CI12.27 to 3.29, P = 0.0007) compared to control group as well as a lesser need for therapeutic intervention (RR 0.49, 95% CI 0. Additionally, there were decreased rates of macrosomia (RR 0.49, 95% CI 0.27-0.88, P = 0.02) and mean birthweight (170.62 g, 95% CI 333.64 to 7.60, P = 0.04). (36)

6.3 **Metformin**- Early in pregnancy, patients with polycystic ovarian syndrome frequently take metformin. If lifestyle changes fail to reach desired glycaemic results, it is also utilised as a medication treatment for GDM in the second and third trimesters. Numerous elements of metformin use during pregnancy have been compiled in a recent review (37).

The only oral medications used to treat GDM are metformin and glibenclamide (marketed as glyburide in the US and Canada). The rate of perinatal problems (32.0% versus 32.2%) and

adverse events in the major randomised Metformin in Gestational Diabetes (MiG) trial did not differ between the metformin and insulin therapy groups (38).

However, the available data do not support the use of metformin as a GDM prevention strategy. In the (EMPOWaR) research, 449 obese women with normal baseline glucose tolerance were randomised to receive up to 2,500 g of metformin per day vs. a placebo between 12 and 16 weeks of pregnancy, and the study lasted until the baby was delivered (39).

From 12 to 18 weeks of pregnancy until delivery, Syngelaki et al. randomly assigned women with a BMI greater than 35 kg/m2 to receive 3 g of metformin or a placebo (40). The trial was completed by 202 metformin-treated women and 198 placebo-treated women. Fetal growth did not alter in any way. Metformin caused a 1.7 kg (P 0.001) decrease in maternal GWG. GDM rates and other pregnancy outcomes were comparable between groups.

6.4 **Fish oil**- Additionally, it has been claimed that dietary fatty acids could be used as a treatment to lower GDM and increase the likelihood of premature birth. Before 21 weeks of pregnancy, 2399 women were randomly assigned to receive either (1) DHA-enriched fish oil 800 mg daily or (41) vegetable oil capsules without DHA until delivery for the DHA to optimise mother-infant outcome (DOMInO) RCT (42). There was no reduction in GDM or preeclampsia, and there were no variations in the size or adiposity of the neonates. A later study of the kids at age 7 revealed no anthropometric differences (43).

6.5 **Vitamin D**- Low serum levels of 25-hydroxyvitamin D are undoubtedly a risk factor for the onset of GDM (44), but treatment trial outcomes have been inconsistent. According to the most recent Cochrane review (45), which mostly included studies from the Middle East, vitamin D supplementation alone "probably" lowers the population frequency of gestational diabetes mellitus (GDM) and pre-eclampsia (RR 0.48 (95% CI 0.30-0.79) cases. However, neither vitamin D + calcium nor vitamin d + calcium + other minerals were found to be beneficial. Therefore, supplementing with vitamin D seems like a sensible choice among groups with low baseline levels. Future research should help to clarify its actual therapeutic function.

7. SUMMARY-

In conclusion, GDM poses a significant short and long-term challenge. The early detection and treatment of GDM are unquestionably beneficial for enhancing outcomes. Mothers and newborns long-term health is also clearly correlated with these factors, although the best course of therapy has yet to be proven. This is a worldwide issue! The NCD burden of GDM as manifested in affected women and their progeny must quickly be reduced through prevention and intervention, both during and after pregnancy. Despite growing understanding in this domain, there are still few practical applications for tried-and-true methods. Widespread adoption of very simple treatments has the potential to significantly reduce the burden of NCDs and stop the "slow motion calamity" of obesity and diabetes, as described by Dr. Margaret Chan, Director of the World Health Organization, in 2017 (46).

REFERENCES:-

1. Cho, Nam H., J. E. Shaw, Suvi Karuranga, Yafang Huang, J. D. da Rocha Fernandes, A. W. Ohlrogge, and B. Malanda. "IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045." *Diabetes research and clinical practice* 138 (2018): 271-281.
2. Vickers NJ. Animal communication: when i'm calling you, will you answer too?. Current biology. 2017 Jul 24;27(14):R713-5.
3. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, Roura LC, McIntyre HD, Morris JL, Divakar H. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2015 Oct;131:S173-211.
4. Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, Lowe LP, Trimble ER, Coustan DR, Hadden DR, Persson B. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes care. 2012 Apr 1;35(4):780-6.
5. Frcog AE. Unravelling the Connection Between Gestational Diabetes Mellitus and Butyrylcholinesterase. Gestational Diabetes. 2011 Nov 2:227.
6. Group HSCR. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: associations with maternal body mass index. BJOG. 2010;117(5):575-84.
7. Yoffe L, Polsky A, Gilam A, Raff C, Mecacci F, Ognibene A, Crispi F, Gratacós E, Kanety H, Mazaki-Tovi S, Shomron N. Early diagnosis of gestational diabetes mellitus using circulating microRNAs. European journal of endocrinology. 2019 Nov 1;181(5):565-77.
8. Abdeltawab A, Zaki ME, Abdeldayem Y, Mohamed AA, Zaied SM. Circulating micro RNA-223 and angiopoietin-like protein 8 as biomarkers of gestational diabetes mellitus. British Journal of Biomedical Science. 2021 Jan 2;78(1):12-7.
9. Filardi T, Catanzaro G, Mardente S, Zicari A, Santangelo C, Lenzi A, Morano S, Ferretti E. Non-coding RNA: role in gestational diabetes pathophysiology and complications. International Journal of Molecular Sciences. 2020 Jan;21(11):4020.
10. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes care. 2007 Jul 1;30(Supplement_2):S141-6.
11. Jiwani A, Marseille E, Lohse N, Damm P, Hod M, Kahn JG. Gestational diabetes mellitus: results from a survey of country prevalence and practices. The Journal of Maternal-Fetal & Neonatal Medicine. 2012 Jun 1;25(6):600-10.
12. Macaulay S, Dunger DB, Norris SA. Gestational diabetes mellitus in Africa: a systematic review. PloS one. 2014 Jun 3;9(6):e97871.
13. Sicree R, Shaw J, Zimmet P. Diabetes atlas international diabetes federation. Belgium: International Diabetes Federation. 2006.
14. Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, Dietz PM. Maternal obesity and risk of gestational diabetes mellitus. Diabetes care. 2007 Aug 1;30(8):2070-6.
15. Lowe WL, Lowe LP, Kuang A, Catalano PM, Nodzenski M, Talbot O, Tam WH, Sacks DA, McCance D, Linder B, Lebenthal Y. Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study. Diabetologia. 2019 Apr;62(4):598-610.

16. Hughes RC, Williman J, Gullam JE. Universal HbA1c measurement in early pregnancy to detect type 2 diabetes reduces ethnic disparities in antenatal diabetes screening: a population-based observational study. PloS one. 2016 Jun 7;11(6):e0156926.
17. Vickers NJ. Animal communication: when i'm calling you, will you answer too?. Current biology. 2017 Jul 24;27(14):R713-5.
18. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. World Health Organization; 2013.
19. Weinert LS. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy: comment to the International Association of Diabetes and Pregnancy Study Groups Consensus Panel. Diabetes care. 2010 Jul 1;33(7):e97-.
20. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, Roura LC, McIntyre HD, Morris JL, Divakar H. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2015 Oct;131:S173-211.
21. Bonongwe P, Lindow SW, Coetzee EJ. Reproducibility of a 75G oral glucose tolerance test in pregnant women. Journal of Perinatal Medicine. 2015 May 1;43(3):333-8.
22. Persson M, Winkvist A, Mogren I. Surprisingly low compliance to local guidelines for risk factor based screening for gestational diabetes mellitus-A population-based study. BMC pregnancy and childbirth. 2009 Dec;9(1):1-0.
23. Whiteside JL. Robotic gynecologic surgery: a brave new world?. Obstetrics & Gynecology. 2008 Dec 1;112(6):1198-200.
24. Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada.
25. Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. American journal of obstetrics and gynecology. 1991 Dec 1;165(6):1667-72.
26. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes care. 2007 Jul 1;30(Supplement_2):S112-9.
27. Buchanan TA, Xiang AH. Gestational diabetes mellitus. The Journal of clinical investigation. 2005 Mar 1;115(3):485-91.
28. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New England journal of medicine. 2005 Jun 16;352(24):2477-86.
29. Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, Lowe LP, Trimble ER, Coustan DR, Hadden DR, Persson B. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes care. 2012 Apr 1;35(4):780-6.
30. Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. Journal of Pediatric Endocrinology and Metabolism. 2001 Sep 1;14(8):1085-92.

31. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New England journal of medicine. 2005 Jun 16;352(24):2477-86.
32. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp Jr JM, Sciscione A. A multicenter, randomized trial of treatment for mild gestational diabetes. New England Journal of Medicine. 2009 Oct 1;361(14):1339-48.
33. Blumer I, Hadar E, Hadden DR, Jovanovič L, Mestman JH, Murad MH, Yogev Y. Diabetes and pregnancy: an endocrine society clinical practice guideline. The journal of clinical endocrinology & Metabolism. 2013 Nov;98(11):4227-49.
34. Metzger BE, Buchanan TA, Coustan DR, De Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes care. 2007 Jul 1;30(Supplement_2):S251-60.
35. during Pregnancy WG. Reexamining the guidelines. Institute of Medicine. 2009.
36. Brown J, Alwan NA, West J, Brown S, McKinlay CJ, Farrar D, Crowther CA. Lifestyle interventions for the treatment of women with gestational diabetes. Cochrane Database of Systematic Reviews. 2017(5).
37. Lowe WL, Lowe LP, Kuang A, Catalano PM, Nodzenski M, Talbot O, Tam WH, Sacks DA, McCance D, Linder B, Lebenthal Y. Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study. Diabetologia. 2019 Apr;62(4):598-610.
38. Catalano HM, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. Nat Rev Dis Primers. 2019 Apr;11:47.
39. Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, Walker BR, Quenby S, Wray S, Weeks A, Lashen H. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. The lancet Diabetes & endocrinology. 2015 Oct 1;3(10):778-86.
40. Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H. Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med. 2016 Feb 4;374:434-43.
41. Vickers NJ. Animal communication: when i'm calling you, will you answer too?. Current biology. 2017 Jul 24;27(14):R713-5.
42. Luo X, Ma X, Hu H, Li C, Cao S, Huang L. Kinetic study of pentosan solubility during heating and reacting processes of steam treatment of green bamboo. Bioresource technology. 2013 Feb 1;130:769-76.
43. Wood K, Mantzioris E, Lingwood B, Couper J, Makrides M, Gibson RA, Muhlhausler BS. The effect of maternal DHA supplementation on body fat mass in children at 7 years: follow-up of the DOMInO randomized controlled trial. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2018 Dec 1;139:49-54.
44. Sadeghian M, Asadi M, Rahmani S, Akhavan Zanjani M, Sadeghi O, Hosseini SA, Zare Javid A. Circulating vitamin D and the risk of gestational diabetes: a systematic review and dose-response meta-analysis. Endocrine. 2020 Oct;70(1):36-47.
45. Palacios C, Kostiuk LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database of Systematic Reviews. 2019(7).

46. Chan M. Obesity and diabetes: The slow-motion disaster. The Milbank Quarterly. 2017 Mar;95(1):11.